Galapagos Says Goodbye To Jyseleca And Streamlines Operations
The Belgium-based biotech is transferring the rights to its only marketed product to Italy’s Alfasigma in a move aimed at cutting costs and tightening its focus on its early-stage immunology and oncology pipeline.
You may also be interested in...
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
The Bologna-based firm is looking to grow its presence in the US as well as in gastrointestinal and liver disease as it acquires Intercept, which received a second rejection for its NASH drug OCA in June.
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.